Prevalence and outcomes of re-positive nucleic acid tests in discharged COVID-19 patients
- PDF / 248,841 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 110 Downloads / 144 Views
BRIEF REPORT
Prevalence and outcomes of re-positive nucleic acid tests in discharged COVID-19 patients Hou-wei Du 1 & Jun-nian Chen 2 & Xiao-bin Pan 3 & Xiao-ling Chen 4 & Yixian-Zhang 5 & Shuang-fang Fang 1 & Xiao-qing Li 6 & Pin-cang Xia 6 & Lei Gao 7 & Hai-long Lin 8 & Li-min Chen 9 & Nan Liu 5 & On behalf of Fujian Medical Team Support Wuhan for COVID-19 Received: 15 June 2020 / Accepted: 26 August 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract The prevalence and outcomes of patients who had re-activation of coronavirus disease 2019 (COVID-19) after discharge remain poorly understood. We included 126 consecutively confirmed cases of COVID-19 with 2-month follow-up data after discharge in this retrospective study. The upper respiratory specimen using a reverse-transcription polymerase chain reaction test of three patients (71 years [60–76]) were positive within 11–20 days after their discharge, with an event rate of 19.8 (95%CI 2.60–42.1) per 1,000,000 patient-days. Moreover, all re-positive patients were asymptomatic. Our findings suggest that few recovered patients may still be virus carriers even after reaching the discharge criteria. Keywords Coronavirus disease 2019 . Re-positive . Infectivity . Follow-up . Outcome
Introduction In December 2019, patients presenting with viral pneumonia due to 2019 novel coronavirus (2019-nCoV) were firstly reported in Wuhan, China [1]. Although the coronavirus disease 2019 (COVID-19) pandemic has been under considerable control in China, a few discharged patients were reported to have re-positivation of 2019-nCoV during their follow-up visits [2, 3]. However, studies on the prevalence, clinical features, timing of viral nucleic acid re-emergence, and
infectivity in these patients are very rare. Monitoring of the coronavirus disease 2019 (COVID-19) prognosis and effective control of the “second wave of an outbreak” of the epidemic remain a huge challenge to the public health. We aimed to describe the prevalence, demographics, clinical features, and laboratory data of viral nucleic acid reemergence by investigating the follow-up data of discharged COVID-19 patients. Our findings may help to better understand the follow-up management of discharged COVID-19 patients.
Hou-wei Du and Jun-nian Chen contributed equally to this work. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10096-020-04024-1) contains supplementary material, which is available to authorized users. * Nan Liu [email protected] 1
Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
2
Department of Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, China
3
Department of Critical Care Medicine, Fujian Provincial Hospital South Branch, Fuzhou, China
4
Department of Infectious Disease, Fujian Medical University Union Hospital, Fuzhou, China
5
Department of Neurology, Department of Rehabilitation, Fujian Medical University Union Hospital, 29 Xinquan Road, Gulou District
Data Loading...
